Insight Into the New Age TB and Malaria Diagnostics
http://www.healthmedicalresources.com/articles/18/1/Insight-Into-the-New-Age-TB-and-Malaria-Diagnostics/Page1.html
Gerald P Njuguna
By Gerald P Njuguna
Published on September 8th, 2008
Anti-psychotic drug that is administered to treat adults and adolescents with schizophrenia in the U.S. With state approval will now most definitely be made available to youngsters suffering from bipolar disorder between the age of 10 - 17 years.
Insight Into the New Age TB and Malaria Diagnostics
Anti-psychotic drug that is administered to treat adults and adolescents with schizophrenia in the U.S. With state approval will now most definitely be made available to youngsters suffering from bipolar disorder between the age of 10 - 17 years.
Bipolar disorder is a condition also referred to as manic-depressive illness. It is essentially a brain disorder that is responsible for extreme mood swings, which in turn has a considerable impact on a person's energy levels and their functional abilities. Millions of people across the globe are subjected to the bipolar disorder. This disorder usually sets in during the time of adolescence or early adulthood.
Such drastic changes in one's mood can lead to damaged relationships, deteriorating performance at one's workplace or in school. When these mood swings reach alarming levels, it could also trigger off an attempt to commit suicide. It is common for people to suffer for many years before this disorder is properly diagnosed and treated.
Priority review status has been accorded by the U.S. Food and Drug Administration (FDA) to the drug named, Abilify, which Bristol-Myers Squibb and Otsuka Pharmaceutical manufactures.
Priority review status is given to products which could offer an improvement in the treatment, diagnosis or prevention of a disease over products already on the market; the review process as a rule takes six months.
The prompting factor behind this priority review has been the promising research results that originated from a study, which was conducted upon 296 pediatric patients with a disorder called bipolar l. The study lasted over a period of approximately 30 weeks during which it was found out that Abilify was both safe and effective after being administered. Abilify and other such anti-psychotic medications have proved to result in increase of weight as well as the risk of being affected by diabetes.
The FDA has sent a sign of acceptance to the drug company’s supplemental approval application that is to be administered to people ranging between the age of between 10 - 17 years, if they are found to be suffering from certain types of bipolar I disorder.
Even though doctors have the permission to prescribe drugs for off-label uses, there is a prohibition in case of drug companies in terms of marketing them for those particular uses that are unapproved by the FDA.
Bipolar disorder is a condition also referred to as manic-depressive illness. It is essentially a brain disorder that is responsible for extreme mood swings, which in turn has a considerable impact on a person's energy levels and their functional abilities. Millions of people across the globe are subjected to the bipolar disorder. This disorder usually sets in during the time of adolescence or early adulthood.
Such drastic changes in one's mood can lead to damaged relationships, deteriorating performance at one's workplace or in school. When these mood swings reach alarming levels, it could also trigger off an attempt to commit suicide. It is common for people to suffer for many years before this disorder is properly diagnosed and treated.
Priority review status has been accorded by the U.S. Food and Drug Administration (FDA) to the drug named, Abilify, which Bristol-Myers Squibb and Otsuka Pharmaceutical manufactures.
Priority review status is given to products which could offer an improvement in the treatment, diagnosis or prevention of a disease over products already on the market; the review process as a rule takes six months.
The prompting factor behind this priority review has been the promising research results that originated from a study, which was conducted upon 296 pediatric patients with a disorder called bipolar l. The study lasted over a period of approximately 30 weeks during which it was found out that Abilify was both safe and effective after being administered. Abilify and other such anti-psychotic medications have proved to result in increase of weight as well as the risk of being affected by diabetes.
The FDA has sent a sign of acceptance to the drug company’s supplemental approval application that is to be administered to people ranging between the age of between 10 - 17 years, if they are found to be suffering from certain types of bipolar I disorder.
Even though doctors have the permission to prescribe drugs for off-label uses, there is a prohibition in case of drug companies in terms of marketing them for those particular uses that are unapproved by the FDA.